<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115762</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-LC-B1202-1</org_study_id>
    <nct_id>NCT03115762</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics,Safety and Immunogenicity of ASKB1202 in Chinese Healthy Subjects: a Randomized, Double-blinded, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the pharmacokinetic,immunogenicity and safety biosimilarity of&#xD;
      ASKB1202 compared to bevacizumab sold in China and Europe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Maximum measured concentration of the analyte in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Terminal-phase elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ASKB1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of ASKB1202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells</description>
    <arm_group_label>bevacizumab A</arm_group_label>
    <arm_group_label>bevacizumab B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASKB1202</intervention_name>
    <arm_group_label>ASKB1202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Healthy males,aged 18 to 50 years. 2.A complete medical history, including disease&#xD;
             history,physical examination, vital signs, 12-lead electrocardiogram (ECG), and chest&#xD;
             X-ray image.&#xD;
&#xD;
             3.Clinical laboratory tests is normal or the abnormality is not clinical significant&#xD;
             determined by researchers.&#xD;
&#xD;
             4.The subjects were willing to take effective contraceptive measures within 2 months&#xD;
             before use of the drug and 6 months after.&#xD;
&#xD;
             5.The subjects could understand the procedures and methods of this study, were willing&#xD;
             to strictly abide the clinical trial plan to complete the test, sign the Informed&#xD;
             Notice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Any evidence of a historical or existing clinically relevant concomitant disease, as&#xD;
             determined by researchers.&#xD;
&#xD;
             2.Acute,chronic active infections during screening of the study and admission(1 day&#xD;
             before treatment),or has a history of active tuberculosis.&#xD;
&#xD;
             3.Hemorrhaged or donated blood (including the components of blood donation)， or&#xD;
             received blood transfusion ≥400 mL within 3 months before screening；Hemorrhaged or&#xD;
             donated blood (including the components of blood donation) ≥200 mL within a month&#xD;
             before the screening .&#xD;
&#xD;
             4.Any finding of abnormality which has clinical significance during the screening of&#xD;
             the clinical tests determined by researchers.&#xD;
&#xD;
             5.Currently suffering from hypertension,abnormal blood pressure during study screening&#xD;
             and hospital admission(1 day before use of drug):systolic blood pressure &gt; 140 mmHg&#xD;
             and/or diastolic blood pressure &gt; 90 mmHg.&#xD;
&#xD;
             6.Any disease causes it to increase the risk of bleeding or thrombosis, such as&#xD;
             bleeding or thrombosis genetic predisposition, or has a history of traumatic&#xD;
             hemorrhage, thromboembolic events, blood coagulation disease and thrombocytopenia&#xD;
             (platelet count &lt;100000/L) or international standardization ratio (INR) is higher than&#xD;
             1.44.&#xD;
&#xD;
             7.Suffered or suffering from clinical significant atopic allergy, hypersensitivity or&#xD;
             allergic reaction, including known or suspected sensitive to one component in drug;&#xD;
             abnormal serum immunoglobulin E (IgE) determined by researchers.&#xD;
&#xD;
             8.Abnormal electrocardiogram (ECG) with clinical significance, such as QTc interphase&#xD;
             is greater than 450 milliseconds.&#xD;
&#xD;
             9.A history of gastrointestinal perforation or any fistula. 10.Has a wound without&#xD;
             healing or fracture in study screening and admission. 11.Orthostatic hypotension,&#xD;
             syncope and dizziness or has a history of shock caused by any reason.&#xD;
&#xD;
             12.Suffered from malignant tumors (except that controlled basal cell carcinoma and&#xD;
             squamous cell carcinoma).&#xD;
&#xD;
             13.Has been vaccinated within 4 weeks before screening , or plan to get the vaccine&#xD;
             during the study period.&#xD;
&#xD;
             14.Has a history of taking beacizumab or anti VEGF targeted agents or having the&#xD;
             antibody of anti VEGF.&#xD;
&#xD;
             15.Participated in another trial within three months prior to administration or had a&#xD;
             monoclonal antibody therapy within twelve months prior to administration.&#xD;
&#xD;
             16.Received a surgery within 28 days prior to administration, including dental suture&#xD;
             or wound dehiscence, or plan to undergo surgery including dental surgery during the&#xD;
             study and 60 days after the last administration of the protocol specified treatment.&#xD;
&#xD;
             17.Used any drug that is harmful to major organs within 3 months before&#xD;
             administration,or use any drug within 14 days prior to participation.&#xD;
&#xD;
             18.Smoker who smoked &gt;5 cigarettes per day within 3 months prior to the research and&#xD;
             unable to refrain from smoking during the research.&#xD;
&#xD;
             19.History of alcohol abuse(drink alcohol more than 14 units a week [1 unit = 285 mL&#xD;
             beer or 25 mL of liquor or 100 mL of wine); positive result for alcohol breath test&#xD;
             within 24h before treatment;or unable to refrain from drinking during the study.&#xD;
&#xD;
             20.History of taking drugs or drug abuse;or positived result for drug screening;or&#xD;
             unable to refrain from drug abuse during the study.&#xD;
&#xD;
             21.Positive hepatitis b surface antigen , hepatitis c antibody , HIV antibody and&#xD;
             syphilis antibody.&#xD;
&#xD;
             22.Any condition that not suitable to anticipate the research or bring obvious risks&#xD;
             to the subjects according to researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASKB1202</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

